ASSOCIATION OF BODY MASS INDEX WITH MORTALITY IN PERITONEAL DIALYSIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Seyed-Foad Ahmadi,¹,² Golara Zahmatkesh,¹ Elani Streja,¹,³ Rajnish Mehrotra,⁴ Connie M. Rhee,¹ Csaba P. Kovesdy,⁵,⁶ Daniel L. Gillen,²,⁷,⁸ Emad Ahmadi,⁹ Gregg C. Fonarow,¹⁰ and Kamyar Kalantar-Zadeh¹,²,³,⁸

Harold Simmons Center for Kidney Disease Research and Epidemiology,¹ Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, California, USA; Department of Population Health and Disease Prevention,² Program in Public Health, University of California Irvine, Irvine, California, USA; Veterans Affairs Long Beach Healthcare System,³ Long Beach, California, USA; Kidney Research Institute and Division of Nephrology,⁴ University of Washington, Seattle, Washington, USA; Memphis Veterans Affairs Medical Center,⁵ Memphis, Tennessee, USA; Division of Nephrology,⁶ University of Tennessee Health Science Center, Memphis, Tennessee, USA; Department of Statistics,⁷ Donald Bren School of Information and Computer Sciences, University of California Irvine, Irvine, California, USA; Department of Epidemiology,⁸ UCLA School of Public Health, Los Angeles, California, USA; Department of Radiology,⁹ Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Division of Cardiology,¹⁰ UCLA David Geffen School of Medicine, Los Angeles, California, USA

♦ Background: Although higher body mass index (BMI) is associated with better outcomes in hemodialysis patients, the relationship in peritoneal dialysis (PD) patients is less clear. We aimed to synthesize the results from all large and high-quality studies to examine whether underweight, overweight, or obesity is associated with any significantly different risk of death in peritoneal dialysis patients.

♦ Methods: We searched MEDLINE, EMBASE, Web of Science, CINAHL, and Cochrane CENTRAL, and screened 7,123 retrieved studies for inclusion. Two investigators independently selected the studies using predefined criteria and assessed each study’s quality using the Newcastle-Ottawa Quality Assessment Scale. We meta-analyzed the results of the largest studies with no overlap in their data sources.

♦ Results: We included 9 studies (n = 156,562) in the systematic review and 4 studies in the meta-analyses. When examined without stratifying studies by follow-up duration, the results of the studies were inconsistent. Hence, we pooled the study results stratified based upon their follow-up durations, as suggested by a large study, and observed that being underweight was associated with higher 1-year mortality but had no significant association with 2- and 3- to 5-year mortalities. In contrast, being overweight or obese was associated with lower 1-year mortality but it had no significant association with 2-, and 3- to 5-year mortalities.

♦ Conclusion: Over the short-term, being underweight was associated with higher mortality and being overweight or obese was associated with lower mortality. The associations of body mass with mortality were not significant over the long-term.

http://dx.doi.org/10.3747/pdi.2015.00052

KEY WORDS: Body mass index; mortality; peritoneal dialysis; meta-analysis; obesity paradox.

Patients with end-stage renal disease undergoing maintenance dialysis therapy have a substantially higher risk of mortality (1). As in patients undergoing maintenance hemodialysis, cardiovascular disease is the main cause of death in patients receiving peritoneal dialysis (PD) (2). Even though in the general population obesity is associated with increased risk of cardiovascular disease and all-cause mortality, the risk of death is lower with increasing body mass (BMI), an indicator of obesity, in patients undergoing maintenance hemodialysis (3,4). Yet among patients undergoing PD, studies examining the association of body mass with mortality have been inconsistent; however, some studies have also linked obesity to lower mortality in this population (5,6). Given the inconsistent associations in studies published to date, we sought to synthesize the results from all large and high-quality studies to examine whether underweight, overweight, or obesity is associated with any significantly different risk of death in PD patients.

METHODS

SEARCH STRATEGIES

We targeted studies investigating the link between BMI and mortality in all chronic kidney disease patients including
those receiving PD. We searched MEDLINE (PubMed), Web of Science, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Central Register of Controlled Trials (CENTRAL) up to July 2013 with no limitation in study type, language, and geographical area. To search PubMed, we used the following search query:

\[ \text{(((Renal Insufficiency, Chronic) OR (chronic renal insufficiency*) OR (Kidney Failure, Chronic) OR (chronic renal failure) OR (end?stage kidney disease*) OR (end?stage renal disease*) OR ESRD OR (chronic kidney disease*) OR (chronic renal disease*) OR (Renal Dialysis) OR ((renal OR kidney) AND dialys*) OR hemodialys* OR haemodialys* OR ((peritoneal OR extracorporeal) AND dialys*) OR Kidney Transplantation OR ((kidney OR renal) AND transplant*)) AND ((body mass index) OR BMI OR overweight OR obes*) AND (mortality OR death rate*) OR (case fatality rate*) OR survival OR (reverse epidemiolog*) OR (obesity AND paradox*)}) \]

A similar query was used to search Web of Science, CINAHL, and CENTRAL. To search EMBASE, the above search query was tailored to match the searching keywords to Emtree (the EMBASE’s indexing thesaurus). Three field experts (RM, CPK, KK-Z) were consulted to identify any unidentified relevant study.

STUDY SELECTION

After importing the search results into EndNote software (Thomson Reuters, New York, NY, USA), we removed duplicated records. Two investigators (SFA, GZ), blinded to the study authors and journals, independently screened the studies for inclusion. The included studies had to describe data from case-control, cohort, or clinical trial studies to test the association of either baseline BMI or change in BMI with all-cause mortality in PD patients. Studies with mixed PD and hemodialysis patients were not included. Also, studies with fewer than 1,000 PD patients were not included as small studies are more likely to be influenced by publication (reporting) bias. Any discrepancies between the 2 reviewers on study eligibility were resolved by discussion and consensus.

DATA ABSTRACTION AND QUALITY ASSESSMENT

We extracted and tabulated the main characteristics and findings of the included studies (Table 1). In addition to all-cause mortality, we also extracted the results regarding technique failure (i.e. transfer to hemodialysis) when available. The corresponding authors of the studies with incomplete data were contacted in order to request further data. To assess the quality of the included studies, the same 2 investigators (SFA, GZ) independently applied the Newcastle-Ottawa Assessment Scale (7) assigning a quality score of 0 – 9 to each study (Supplementary Table S4). The quality score was based on 3 major components: selection of study participants (0 – 4 points), quality of the adjustment for confounding (0 – 2 points), and ascertainment of the exposure or outcome of interest in case-control studies or cohorts, respectively (0 – 3 points). The maximum score was 9 points, representing the highest methodological quality. Disagreements in the scores were resolved by discussion and consensus.

DATA ANALYSIS AND SYNTHESIS

We quantified the inter-rater agreement for selection of studies and assessment of quality.

For meta-analyses, we pooled the summary estimates of association between BMI and mortality. The summary estimates of association between BMI and technique failure were not pooled together as technique failure was a post-hoc outcome in our study and it was not targeted in our search strategies. We assessed statistical heterogeneity using I2 statistic. Summary statistics with a corresponding I2 ≤ 25% were pooled using fixed-effects meta-analysis while summary statistics with a corresponding I2 > 25% were pooled using a random-effects model. The small number of studies included in the meta-analyses prevented us from investigating the risk of publication bias using funnel plots and Egger’s tests of asymmetry. A 95% confidence interval (CI) with no overlap with the null effect value (hazard ratio [HR] = 1) was considered significant in our study. For statistical procedures, we used Stata 12 (StataCorp, College Station, TX, USA).

RESULTS

The retrieved 7,123 citations were screened for inclusion based on their titles/abstracts after duplicated records were removed. Subsequently, 442 citations were evaluated based on their full text article (Figure 1). We finally included 61 studies of the association of BMI with mortality in chronic kidney diseases, and segregated the 8 studies of patients who received PD (Table 1) (8–15). An additional study was identified through consulting field experts (16). All included studies comprised cohorts from pre-existing registry data and reported hazard ratios (HRs) from survival regression models. The utilized registries included the United States Renal Data System (USRDS) (11,13–16), the Australian and New Zealand Dialysis and Transplantation Registry (ANZDATA) (10,12), the Canadian Organ Replacement Register (CORR) (9), and the Brazilian Peritoneal Dialysis Multicenter Study (BRAZPD) (8). All included studies had a low risk of bias with a quality score range of 7 to 9 out of 9 (Supplementary Table S2). Agreement between the 2 investigators was 94% (Kappa: 0.77) for the study selection and 94% (Kappa: 0.78) for the quality assessment.

ASSOCIATION OF BMI WITH ALL-CAUSE MORTALITY

Numerical results are summarized in Supplementary Table S5. Badve et al. (12) and Abbott et al. (14) reported baseline BMI to have no significant association with all-cause mortality in PD patients. On the other hand, McDonald et al. (10) reported that in comparison with BMI
### TABLE 1
Characteristics of Included Studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Data sources and settings</th>
<th>Participants</th>
<th>% Female</th>
<th>Age</th>
<th>Baseline BMI variable</th>
<th>Main analysis</th>
<th>Follow-up</th>
<th>Summary of results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Studies included in meta-analyses:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fernandes et al. (2013) (8)</td>
<td>Data from 114 dialysis centers participating in “Brazilian Peritoneal Dialysis Multicenter Cohort Study,” 2004–2007, Brazil</td>
<td>1,911 incident PD patients ≥18 yo, remained on PD ≥90 days, and have available data</td>
<td>54%</td>
<td>Mean: 59; SD: 16</td>
<td>Ordinal: &lt;18.5 (underweight), 18.5–24.9 (normal BMI), 25.0–29.9 (overweight), ≥30.0 (obese); Also continuous; This study also had a weight change variable</td>
<td>Multivariate Cox regression analysis to calculate HRs of all-cause mortality with baseline BMI categories and with normalized weight change categories</td>
<td>Median: 13 months; Range: 3–34 months</td>
<td>A) Underweight status was associated with higher mortality and overweight/obese statuses associated with lower mortality; B) A weight decrease of &gt;3.1% was associated with higher mortality</td>
</tr>
<tr>
<td>Pliakogiannis et al. (2007) (9)</td>
<td>“Canadian Organ Replacement Registry” data, 1994–2003, Canada</td>
<td>4,054 incident PD patients ≥18 yo, initiated PD between 1994 and 1998</td>
<td>43%</td>
<td>Mean: 58; SD: 15.4; Range: 18–94</td>
<td>Ordinal: &lt;18.5 (underweight), 18.5–24.9 (normal BMI), 25.0–29.9 (overweight), ≥30.0 (obese); Also binary: &lt;30 vs &gt;30</td>
<td>Multivariate Cox regression analysis to calculate HRs of all-cause mortality with baseline BMI categories</td>
<td>Mean: 4.31 years; SD: 2.3 years; Range: 0.1–8.0 years</td>
<td>A) Underweight status was associated with higher mortality, but overweight/obese statuses had no bearing on mortality; B) A trend existed towards a survival benefit of obesity during the first 3 years, but it was reversed after the fourth year</td>
</tr>
<tr>
<td>McDonald et al. (2003) (10)</td>
<td>“Australia and New Zealand Dialysis and Transplant Registry” data, 1991–2002, Australia and New Zealand</td>
<td>9,679 incident PD patients ≥15 yo</td>
<td>47.8%</td>
<td>Mean: 60.5</td>
<td>Ordinal: ≤19.9 (underweight), 20.0–24.9 (normal BMI), 25.0–29.9 (overweight), ≥30.0 (obese); Also continuous</td>
<td>Multivariate Cox regression analysis to calculate HRs of A) all-cause mortality and B) death-censored transfer to hemodialysis with baseline BMI categories</td>
<td>17,973 person-years</td>
<td>A) Underweight and overweight statuses did not have any bearing on mortality, but obesity was associated with higher mortality. In addition, additional analyses linked BMI around 20 to the lowest mortality risk; B) Underweight status did not have any bearing on technique failure, but overweight/obese statuses were associated with higher technique failure rates</td>
</tr>
<tr>
<td>Snyder et al. (2003) (11)</td>
<td>“Form 2728” of Center for Medicare and Medicaid data, 1995–2000, US</td>
<td>41,197 incident PD patients ≥18 yo who were on PD ≥60 days</td>
<td>47%</td>
<td>18–29 yo: 5%; 30–44 yo: 17%; 45–64 yo: 41%</td>
<td>Ordinal: &lt;18.5 (underweight), 18.5–24.9 (normal BMI), 25.0–29.9 (overweight), ≥30.0 (obese)</td>
<td>Multivariate Cox regression analysis to calculate HRs of all-cause mortality with</td>
<td>Max: 3 years</td>
<td>A) Differential BMI–mortality associations were observed based upon the follow-up duration (explained in text); B) For BMI–technique failure association, underweight status had</td>
</tr>
</tbody>
</table>
TABLE 1 (cont’d)
Characteristics of Included Studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Data sources and settings</th>
<th>Participants</th>
<th>% Female</th>
<th>Age</th>
<th>Baseline BMI variable</th>
<th>Main analysis</th>
<th>Follow-up</th>
<th>Summary of results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Snyder et al. (2003) (11) cont’d.</td>
<td></td>
<td>65+ yo: 37%</td>
<td>baseline BMI categories</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>no bearing on technique failure while overweight/obese statuses were linked to higher technique failure until the first year; the results were the same until the second year; until the third year, underweight status still had no bearing on technique failure, overweight status no longer had a bearing on it, and obesity still had a direct association with it</td>
</tr>
</tbody>
</table>

Studies excluded from meta-analyses:

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Data sources and settings</th>
<th>Participants</th>
<th>% Female</th>
<th>Age</th>
<th>Baseline BMI variable</th>
<th>Main analysis</th>
<th>Follow-up</th>
<th>Summary of results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mehrrotra et al. (2009) (16)</td>
<td>“United States Renal Data System” data, 1996–2004, US 66,381 incident PD patients (42,942 CAPD and 23,439 APD), remained on PD ≥90 days</td>
<td>47%</td>
<td>CAPD: Mean: 56.4; SD: 15.1; APD: Mean: 57.1; SD: 15.6</td>
<td>Ordinal: &lt;21.88, 21.88–24.61, 24.61–27.43, 27.43–31.37, &gt;31.37</td>
<td>Multivariate exponential piecewise survival models to calculate HRs of A) all-cause mortality and B) technique failure (transfer to HD for &gt;60 days) with baseline BMI categories</td>
<td>Median for CAPD: 18.3 months; Median for APD: 17.6 months</td>
<td>Higher BMI quintiles were linked to lower mortality, but they were associated with higher technique failure rates</td>
<td></td>
</tr>
<tr>
<td>Badve et al. (2008) (12)</td>
<td>“Australia and New Zealand Dialysis and Transplant Registry” data, 1999–2004, Australia and New Zealand 4,128 incident PD patients</td>
<td>47%</td>
<td>Mean: 58.2; SD: 16.0</td>
<td>Ordinal: ≤19.9 (underweight), 20–24.9 (normal BMI), 25–29.9 (overweight), ≥30 (obese); Also continuous</td>
<td>Univariate Cox regression analysis to calculate HRs of A) all-cause mortality and B) death-censored transfer to HD with baseline BMI categories</td>
<td>6,981 person-years</td>
<td>A) Underweight and overweight/obese statuses had no bearing on mortality; B) Underweight and overweight statuses had no bearing on technique failure, but obese status was linked to higher technique failure</td>
<td></td>
</tr>
<tr>
<td>Study ID</td>
<td>Data sources and settings</td>
<td>Participants</td>
<td>% Female</td>
<td>Age</td>
<td>Baseline BMI variable</td>
<td>Main analysis</td>
<td>Follow-up</td>
<td>Summary of results</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------------------------</td>
<td>--------------</td>
<td>----------</td>
<td>-----</td>
<td>-----------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ramkumar et al. (2005) (13)</td>
<td>“Form 2728” of Center for Medicare and Medicaid and “United States Renal Data System” data, 1995–1999, US</td>
<td>10,140 incident PD patients ≥ 18 yo with no previous RRT, complete follow-up, and available data</td>
<td>52.50%</td>
<td>Mean: 59.1; SD: 14.9</td>
<td>Ordinal: 18.5–24.9 (normal BMI), ≥ 25 (high BMI) [no participant with BMI &lt; 18.5]</td>
<td>Multivariate Cox regression analysis to calculate HRs of all-cause and cardiovascular mortality with baseline categories of BMI/urine Cr</td>
<td>17,500 person-years</td>
<td>Higher BMI values were linked to lower all-cause and cardiovascular mortality only in those with normal/high urine creatinine (as a surrogate for high muscle mass), but in patients with low urine creatinine (as a surrogate for low muscle mass), mortality was not different between those with normal and high BMI values</td>
</tr>
<tr>
<td>Abbott et al. (2004) (14)</td>
<td>“United States Renal Data System Dialysis Morbidity and Mortality Wave II” data (including all PD and a 20% random sample of HD patients), 1996–2001, US</td>
<td>1,662 incident PD (plus 1,975 hemodialysis) patients who started dialysis in 1996, remained on dialysis ≥ 90 days, had valid BMI</td>
<td>46.50%</td>
<td>Mean: 56.3; SD: 157</td>
<td>Ordinal (based on BMI quartiles): &lt; 21.9, 22–24.9, 25–29.9, ≥ 30; and Binary: &lt; 30, ≥ 30</td>
<td>Multivariate Cox regression analysis to calculate HRs of all-cause mortality with baseline BMI categories</td>
<td>Max: 5 years</td>
<td>This study did not observe any BMI–mortality association through analyzing BMI quartiles as well as the 2 groups of obese/non-obese</td>
</tr>
<tr>
<td>Stack et al. (2005) (15)</td>
<td>“Medical Evidence Form” of Center for Medicare and Medicaid and “United States Renal Data System” data, 1995–1997, US</td>
<td>17,410 incident PD patients (and a total of 101,081 incident ESRD patients) ≥ 18 yo, started dialysis between 1995 and 1997, remained on dialysis ≥ 90 days, had valid BMI</td>
<td>N/A</td>
<td>N/A</td>
<td>Ordinal (based on BMI quintiles): 8.8–20.9, 29.9–23.5, 35–36.1, 26.1–30.0, 30.0–75.2</td>
<td>Multivariate Cox regression analysis to calculate HRs of all-cause mortality with baseline BMI categories in subgroups of diabetics and non-diabetics</td>
<td>Max: 2 years; Median: 1 year</td>
<td>Lowest BMI quintile was linked to higher mortality; however, other BMI quintiles did not show any bearing on mortality</td>
</tr>
</tbody>
</table>

ID = identification; BMI = body mass index; yo = years old; PD = peritoneal dialysis; SD = standard deviation; HR = hazard ratio; CAPD = continuous ambulatory PD; APD = automated PD; RRT = renal replacement therapy; ESRD = end-stage renal disease; N/A = not available.
of 20.0 – 24.9 (normal), only BMI ≥ 30.0 (obese) was associated with higher mortality while there was no significant difference in risk for death among the other groups of BMI. In addition, there was no demonstrable association between BMI and mortality in the subset of their participants with Maori/Pacific Islander racial origins. In contrast, Pliakogiannis et al. (9) demonstrated an association only of BMI < 18.5 (underweight) with a higher mortality compared to BMI of 18.5 – 24.9 (normal). The trend for better survival in those with BMI ≥ 30 (obese) did not reach statistical significance. Similarly, Stack and Molony (15) reported that in both subgroups of diabetics and non-diabetics, BMI < 20.9 (lowest quintile) was associated with significantly higher mortality compared with BMI of 23.5 – 26.1 (middle quintile), while there was no significant difference in risk for death among individuals in other BMI quintiles. Also, Fernandes et al. (8) reported that in comparison with BMI of 18.5 – 24.9 (normal), BMI of < 18.5 (underweight) was associated with higher mortality while BMI of 25.0 – 29.9 (overweight) and BMI of ≥ 30.0 (obese) were associated with lower mortality. In the largest included study, Mehrotra et al. (16) showed that compared with the lowest quintile of BMI, all higher quintiles were associated with significantly lower mortality. However, if the second quintile (BMI of 21.88 – 24.61) was set as the reference group, only the third quintile (BMI of 21.88 – 24.61) would be associated with a significantly lower mortality. Additionally, Ramkumar et al. (13) reported that BMI ≥ 25.0 (obese) was associated with lower all-cause and cardiovascular mortality but only in patients with urine creatinine of > 0.64 grams/day (g/d) as a surrogate of high muscle mass. In contrast, in patients with urine creatinine of ≤ 0.64 g/d, all-cause and cardiovascular mortality were
not significantly different for BMI of 18.5 – 24.9 (normal) and BMI ≥ 25.

In the study by Snyder et al. (11), the association of baseline BMI with 1-, 2-, and 3-year mortality risk were shown to be different. The investigators categorized BMI values into < 18.5 (underweight), 18.5 – 24.9 (normal; the reference group), 25.0 – 29.9 (overweight), and ≥ 30.0 (obese), and showed that during the first year of PD, being underweight was associated with higher mortality while being overweight and obese were associated with lower mortality. Considering the first 2 years, being underweight continued to be associated with higher mortality and being overweight continued to be associated with lower mortality; however, being obese was no longer associated with significantly different mortality. In a 3-year follow-up, being underweight or overweight were no longer associated with a differential mortality risk while being obese was associated with significantly higher mortality in contrast to its 1-year effect.

Fernandes et al. (8) also assessed the association of weight change (in addition to the baseline BMI) with all-cause mortality in PD patients. They observed that a ≥ 3.1% decrease in normalized weight was associated with a significantly higher mortality.

### META-ANALYSIS OF ALL-CAUSE MORTALITY RESULTS

Four studies were included in meta-analyses (8–11). The selected studies used the WHO BMI classification system (17) and reported corresponding hazard ratios (HRs) of all-cause mortality for underweight, overweight, and obese BMI classes at baseline compared with those with normal BMI. The studies excluded from meta-analyses had substantial overlap in the utilized data sources with the selected studies: Badve et al. (12) overlapped with McDonald et al. (10), and the remaining 4 studies (13–16) overlapped with Snyder et al. (11).

As Snyder et al. (11) reported differential associations of baseline BMI with 1-, 2-, and 3-year mortalities, we stratified the meta-analyses based on the follow-up durations: The median/mean follow-up durations of the studies by Fernandes et al. (8), McDonald et al. (10), and Pliakogiannis et al. (9) were 1.08, 1.86, and 4.31 years, respectively. Therefore, the HRs from these studies were pooled with the Snyder et al. (11) 1-, 2-, and 3-year HRs, respectively (Figures 2 to 4). Our meta-analyses showed that being underweight at baseline was associated with higher 1-year mortality, being overweight with lower 1-year mortality (Figures 2 and 5). Although the pooled association of the obese BMI class with 1-year mortality was

---

**Figure 2** — Forest plots showing the association of baseline BMI classes with 1-year mortality. A, B, and C illustrate the meta-analysis of the hazard ratios (HRs) of 1-year mortality in ‘underweight,’ ‘overweight,’ and ‘obese’ BMI classes, respectively, compared with normal BMI. The BMI cut-points between the ‘underweight,’ ‘normal BMI,’ ‘overweight,’ and ‘obese’ classes were 18.5, 25.0, and 30.0, respectively. The horizontal axes are in logarithmic scale. ID = identification; HR = hazard ratio; BMI = body mass index.
not significant, both meta-analyzed studies (8,11) showed that being obese at baseline was associated with lower 1-year mortality (Figure 2C). The meta-analyses also showed that compared with the normal BMI class, the trend of the association of underweight, overweight, and obese statuses at baseline with 2-year and 3- to 5-year mortality risk did not reach statistical significance (Figures 3, 4, and 5).

**ASSOCIATION OF BMI WITH TECHNIQUE FAILURE**

Four included studies also investigated the association of baseline BMI with technique failure, i.e. transfer to hemodialysis (Supplementary Table S6) (10–12,16). Mehrotra et al. (16) reported that compared with the lowest BMI quintile, higher BMI quintiles were associated with higher risks of technique failure. Also, Badve et al. (12) reported that technique failure was more likely for a BMI ≥ 30 (obese) compared with a BMI of 20.0 – 24.9 (normal). In the study by McDonald et al. (10) BMI of 25.0 – 29.9 (overweight) and ≥ 30.0 (obese) were observed to be associated with a higher risk of technique failure. Similarly, Snyder et al. (11) reported that a BMI of 25.0 – 29.9 (overweight) and a BMI ≥ 30.0 (obese) were associated with higher risks of 1- and 2-year technique failure. Also, a BMI ≥ 30.0 (obese) was still associated with a higher risk of 3-year technique failure.

**DISCUSSION**

To the best of our knowledge, this is the first meta-analysis of published studies evaluating the association of BMI with mortality in PD patients. When examined without stratifying studies by follow-up duration, the results of the included studies were inconsistent. Hence, we pooled study results derived from similar follow-up durations and observed that being underweight at baseline was associated with a higher 1-year mortality but had no significant association with 2- and 3- to 5-year mortalities. Being overweight or obese at baseline was associated with lower 1-year mortality but had no significant association with 2-, and 3- to 5-year mortalities. It is worth noting that although our meta-analysis yielded a non-significant pooled association of obesity with 1-year mortality, the association was significant in both meta-analyzed studies (Figure 2C). (8,11) This phenomenon rarely happens when, in spite of the similar direction of association, the magnitude of association is considerably different among the pooled results. In this case, the pooled confidence
interval may be disproportionately widened. However, the pooled association should be considered significant. Unlike BMI–mortality association, technique failure (i.e. transfer to hemodialysis) rates were reportedly higher with incremental BMI values.

A number of studies have demonstrated a lower risk of death in obese individuals in certain populations such as incident hemodialysis patients, hospitalized patients, elderly nursing home residents, and those with stroke or congestive heart failure (5,18–24). This phenomenon is termed the “obesity paradox” or “reverse epidemiology” and there are several possible explanations for it (5,23). We observed that in PD patients, being overweight or obese at baseline was associated with lower risk of death over the short term. This finding may potentially be due to the contrasting long- and short-term consequences of obesity: Although obesity generally increases the risk of cardiovascular mortality over the long term, it may attenuate the short-term risk of death due to malnutrition, inflammation, and protein-energy wasting (25). Notably, one of the included studies reported that in PD patients, weight loss was associated with a higher risk of death (8). However, this study did not examine whether weight loss was due to the loss of adipose tissue or muscle mass. Studies of hemodialysis patients (26,27) suggest that concurrent weight loss and muscle mass gain is associated with greater survival compared with concurrent weight gain and muscle mass loss. Also, an included study (13) suggested that the protective effect of a baseline BMI $\geq 25$ may be due to higher muscle mass rather than higher adiposity. However, in PD patients, the relative influence of muscle mass or adiposity is difficult to evaluate because of limited epidemiologic evidence. In hemodialysis patients, a few studies have examined whether adiposity and muscle mass have differential associations with mortality; however, their results have not provided a consistent association (5). Also, since BMI can substantially change over time, the use of BMI at baseline rather than BMI as a time-varying covariate may have contributed to the loss of significant associations over longer follow-up durations. For technique failure, on the other hand, the association with BMI was rather direct and not paradoxical. This is possibly because malnutrition does not have a significant bearing on the common causes of technique failure such as mechanical and infectious complications as well as the inadequate solute clearance and/or ultrafiltration (28).

As our results are derived from observational studies, they cannot be used to drive weight-management interventions.

Figure 4 — Forest plots showing the association of baseline BMI classes with 3- to 5-year mortality. A, B, and C illustrate the meta-analysis of the hazard ratios (HRs) of 3- to 5-year mortality in ‘underweight,’ ‘overweight,’ and ‘obese’ BMI classes, respectively, compared with normal BMI. The 3 BMI cut-points between the ‘underweight,’ ‘normal BMI,’ ‘overweight,’ and ‘obese’ classes were 18.5, 25.0, and 30.0, respectively. The horizontal axes are in logarithmic scale. ID = identification; HR = hazard ratio; BMI = body mass index.
However, in the absence of clinical trials, our findings can inform clinical practice by emphasizing that individual patient characteristics should influence decision-making regarding weight management, for example in obese PD patients with short life expectancy, it may not be necessary to advocate weight loss, whereas this may potentially be helpful in those with longer life expectancy.

In this systematic review, we searched multiple databases using sensitive search strategies. Moreover, we only included large studies (i.e. those with ≥ 1,000 patients undergoing PD) that provided higher accuracy and lower likelihood of publication bias. Furthermore, our study selection and quality assessment were carried out in duplicate. However, our study possesses the inherent limitations of systematic reviews of observational studies. Although the included studies represent the largest and highest-quality observational studies on the subject, their results were adjusted for only recognized and measured confounders. In addition, the included studies were from different geographical areas and they had different ranges of BMI values. Moreover, we were not able to run formal tests of publication bias due to the limited number of included studies in each meta-analysis. Furthermore, we used BMI as a surrogate of obesity even though it does not provide accurate information about adiposity or body composition. Nevertheless, BMI is still used in clinical practice to drive weight management and hence our results have clinical relevance.

In conclusion, over short-term follow-up, being underweight was associated with a higher risk of death and being overweight or obese with a lower risk of death. The associations were not significant over long-term follow-up. It is plausible that, despite its long-term consequences, obesity may in fact favorably impact short-term outcomes by attenuating the risk of malnutrition.

DISCLOSURE

RM has served as an ad hoc consultant for Baxter Healthcare. CPK is an employee of the US Department of Veterans Affairs. Opinions expressed in this paper are those of the authors and do not represent the official opinion of the US Department of Veterans Affairs. GCCh reports significant consulting for Novartis, and modest consulting for Amgen, Bayer, Gambro, Medtronic, and Janssen. KK-Z has received honoraria and/or research grants from Abbott, DaVita, Fresenius, Genzyme, and Shire. This work was supported by the NIH/NIDDK K24 DK091419 grant (KK-Z) and philanthropist grants from Mr. Harold Simmons and Mr. Louis Chang.

REFERENCES

15. Stack AG, Murthy BVR, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among “large” ESRD patients in the United States.


